Follow-Up Care in Telehealth Ketamine Programs

Starting a ketamine treatment course is just the beginning of a clinical relationship. What happens after the initial sessions—how your provider monitors your response, adjusts your treatment, and plans for the long term—is a critical determinant of whether you achieve lasting benefit. This article covers what robust follow-up care looks like and what you should expect from your telehealth ketamine provider.

Why Follow-Up Care Matters

Ketamine therapy is not a one-size-fits-all intervention. Individual responses vary significantly based on factors including the underlying condition being treated, the dose administered, the patient's prior treatment history, and the quality of integration work. Without systematic follow-up, a provider cannot know whether treatment is working, whether the dose needs adjustment, or whether a patient is developing concerning patterns.

Follow-up care also addresses the well-established phenomenon of relapse and tolerance. Understanding what to expect from telehealth ketamine therapy helps set realistic expectations for the treatment arc. Ketamine's antidepressant effects are time-limited without continued treatment—most patients experience symptom return within days to weeks of stopping. Managing long-term treatment requires careful monitoring and planning.

Components of Good Follow-Up Care

1. Scheduled Post-Session Check-Ins

Following each session, a brief check-in with a care guide or provider should occur. This typically happens via:

• A video call the day after the session (for higher-dose protocols)
• A secure message or brief call on the day of the session (common in subscription models)
• An app-based reporting tool that captures symptom status and alerts providers to concerning responses

Post-session check-ins serve immediate safety functions: confirming the patient has returned to baseline, identifying any adverse effects that developed, and capturing initial impressions of the experience for the clinical record.

2. Mid-Program Provider Review

After 2-3 sessions of an initial treatment course, the prescribing provider should conduct a clinical review. This involves:

• Symptom re-assessment: Using validated scales (PHQ-9, GAD-7, PCL-5, or similar) to compare current symptom severity to baseline
• Dose review: Determining whether the current dose is appropriate—too low (inadequate effect), too high (overwhelming or adverse effects), or well-calibrated
• Tolerance assessment: Monitoring for early signs of tolerance or dependency
• Integration review: Discussing how integration is proceeding and whether additional support is needed

This mid-course review allows for real-time adjustment of the treatment protocol rather than waiting until the entire initial course is complete.

3. End-of-Course Evaluation

At the completion of the initial treatment course (typically 6 sessions), a comprehensive evaluation should occur. This appointment—usually a full video visit—covers:

• Response assessment: How much has symptom severity changed from baseline? Is the patient a responder, partial responder, or non-responder?
• Functional outcomes: Beyond symptom scores, has daily functioning improved? Sleep, work performance, relationships, activity engagement?
• Adverse effects: Any cardiac concerns, persistent cognitive effects, dissociative symptoms, or signs of problematic use?
• Treatment planning: What comes next? Maintenance dosing, continuation at the same frequency, a rest period, or escalation to in-person IV treatment?

4. Maintenance Treatment Planning

For patients who respond to the initial course, the question becomes: how do we maintain the benefit? Options typically include:

Maintenance Dosing: Scheduled sessions on a less frequent basis—often every 2-4 weeks—to sustain therapeutic effects. The frequency is individualized based on how long each patient's response lasts.

As-Needed Dosing: Some patients with strong initial responses maintain for months before experiencing symptom return. These patients may use ketamine on an as-needed basis when they feel their symptoms returning, rather than on a fixed schedule.

Combination with Other Treatments: Most providers recommend that ketamine therapy not be used in isolation indefinitely. Combining it with ongoing psychotherapy, lifestyle changes, and where appropriate, other medications provides a more durable foundation.

Treatment Holidays: Periodically reassessing whether ketamine is still needed—rather than continuing indefinitely—is good clinical practice. Some patients achieve remission and do not need continued dosing.

5. Monitoring for Adverse Effects Over Time

Long-term ketamine use carries risks that require ongoing monitoring:

Urinary tract effects: Heavy recreational ketamine use is associated with serious bladder damage (ketamine cystitis), characterized by urgency, frequency, and pain. While therapeutic doses are far lower than recreational use levels, providers should periodically ask about urinary symptoms.

Cognitive effects: Some studies suggest possible effects on memory and cognition with high-dose, frequent use. Monitoring for cognitive changes over a treatment course is appropriate, especially for patients receiving higher doses.

Psychological dependency: While ketamine's physical dependence potential is lower than opioids or benzodiazepines, psychological dependence—craving sessions, using ketamine to avoid difficult emotions—can develop. Signs include increasing frequency requests, dysphoria between sessions, or loss of interest in integration work. These warrant clinical attention. For a deeper look at safeguards, see our article on preventing misuse in telehealth ketamine programs.

Cardiovascular monitoring: Regular blood pressure tracking, reported before each session, creates a longitudinal record that allows the provider to detect trends.

What Distinguishes Strong vs. Weak Follow-Up Care

Markers of Strong Follow-Up Care

• Validated symptom scales administered at baseline, mid-course, and end-of-course
• Dose adjustments based on clinical response, not just patient request
• Explicit monitoring for adverse effects including urinary, cognitive, and cardiovascular
• Clear written criteria for when treatment should be modified, paused, or stopped
• A plan for transition out of ketamine therapy when appropriate
• Collaboration with outside providers (therapists, psychiatrists) with patient consent

Markers of Weak Follow-Up Care

• No validated symptom tracking—progress assessed only through informal conversation
• Automatic renewal of prescriptions without clinical review
• No monitoring for adverse effects
• No maintenance planning—the program simply continues indefinitely without reassessment
• Difficulty reaching a provider when concerns arise between scheduled appointments
• No clear protocol for patients who develop warning signs of misuse or adverse effects

Your Role in Follow-Up

Follow-up care is not only the provider's responsibility. As a patient in a telehealth program, you play a central role:

• Complete symptom assessments honestly. Inflating your progress (to please your provider) or minimizing symptoms (to avoid changes to the plan) both undermine care quality.
• Report adverse effects promptly. Do not wait for your next scheduled check-in to mention concerning physical or psychological changes.
• Engage with integration work. Your provider can track symptom scores; only you can report on the deeper work of using the ketamine window for lasting change.
• Ask about the long-term plan. If your provider has not discussed what maintenance looks like or when treatment might end, ask. You deserve a clear clinical rationale for the plan.

Good telehealth follow-up care turns a series of sessions into a coherent treatment trajectory with a beginning, middle, and thoughtfully planned end.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service